Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.
- Licence & Supply Agreement signed with Cadila for two generic cardiovascular and metabolic drugs
- Algorae to manage TGA sponsorship and commercialisation via AlgoraeRx
- Partnership complements existing oncology licensing and distribution deals
- Cadila responsible for product development and manufacturing
- First shipment of Capecitabine received under Dr. Reddy’s distribution agreement
Strategic Expansion into Cardiovascular and Metabolic Markets
Algorae Pharmaceuticals Limited (ASX, 1AI) has taken a significant step in diversifying its commercial portfolio with the execution of a definitive Licence & Supply Agreement (LSA) with Cadila Pharmaceuticals. This agreement targets the launch of two generic medicines addressing cardiovascular and metabolic disorders in Australia and New Zealand (ANZ), marking Algorae’s expansion beyond its established oncology focus.
Under the terms of the deal, Cadila Pharmaceuticals, a major Indian pharmaceutical company known for its integrated manufacturing and R&D capabilities, will develop and manufacture the products. Algorae, through its subsidiary AlgoraeRx, will assume the role of Therapeutic Goods Administration (TGA) sponsor, overseeing regulatory submissions and commercialisation efforts across the ANZ region.
Building a Multi-Therapy Commercial Platform
This new partnership complements Algorae’s existing agreements, including an exclusive licensing deal with Sakar Healthcare Limited for five generic oncology medicines and a distribution agreement with Dr. Reddy’s Laboratories for Capecitabine 500 mg tablets, a chemotherapy drug recently introduced to the Australian market. Together, these collaborations establish a robust, multi-partner commercial platform spanning oncology, cardiovascular, and metabolic therapies.
Algorae’s strategy leverages its AI-enabled drug discovery capabilities alongside a growing commercialisation arm, positioning the company to serve a broad spectrum of hospital, pharmacy, and institutional customers in ANZ. The company’s approach reflects a deliberate effort to diversify revenue streams and deepen its footprint in generic pharmaceuticals.
Next Steps and Market Implications
Algorae is now preparing for TGA registration planning and documentation for the Cadila products, with updates on submission timelines, launch windows, and revenue expectations to follow. The company’s commercial division continues to explore additional opportunities, signaling ongoing momentum in its commercial expansion.
For Cadila, this agreement reinforces its global reach, leveraging its manufacturing excellence and regulatory experience to enter the ANZ market through a trusted local partner. For Algorae, it represents a strategic broadening of its product portfolio, potentially enhancing its market relevance and financial performance in the near to medium term.
Bottom Line?
Algorae’s Cadila deal signals a promising diversification beyond oncology, with regulatory milestones now in focus.
Questions in the middle?
- When will Algorae submit the TGA applications for the new cardiovascular and metabolic generics?
- What are the anticipated launch dates and revenue projections for these new products?
- How will Algorae balance its AI-driven R&D focus with its expanding commercial portfolio?